Results of the phase 3 ELOQUENT-2 trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Prof Sagar Lonial at Annual Meeting 2015 - 101271

Spotlight
Video

Results of the phase 3 ELOQUENT-2 trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Prof Sagar Lonial at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/19/15
Added : 3 years ago
Category : Multiple Myeloma



Recommended

Nothing found.

More From EMJ

Nothing found.